Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUC-101
- Development stage
- Preclinical
- Lead developer
- Lucina Biotherapeutics
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravitreal
01
Overview
LUC-101 is a synthetic lipid therapeutic being developed by Lucina Biotherapeutics for the treatment of dry age-related macular degeneration (AMD) and Stargardt Type 3 macular dystrophy. It is a proprietary intravitreal formulation of C24:5n-3, a very long-chain polyunsaturated fatty acid (VLC-PUFA). The drug is part of the PUFActive platform, which aims to replenish critical lipids that naturally decline in retinal tissues with age and disease. By restoring VLC-PUFA concentrations, LUC-101 is designed to rejuvenate retinal cells and reverse aging-related dysfunction, potentially acting as a disease-modifying therapy. Research has demonstrated that targeted replenishment of these essential membrane lipids can restore retinal structure and function in animal models. LUC-101 is currently in IND-enabling studies.
- Other names
- C24:5n-3synthetic VLC-PUFAsynthetic lipid
Beyond the preview
Go deeper on LUC-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUC-101.